FDA
-
-
-
-
-
-
-
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic C
-
-
-
-
-
-
-
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
-
-
-
-
-
-
-
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma
-
-
-
-
-
-
-
Adaptive Biotechnologies (ADPT) Appoints Tycho Peterson as CFO
-
-
-
-
-
-
-
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results
-
-
-
-
-
-
-
Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients
-
-
-
-
-
-
-
Adaptive Biotechnologies (ADPT) Will Present New SARS-CoV-2 Data from its Immune Medicine Platform at IDWeek 2021
-
251,728 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All